KRAS and lung carcinoma: When combined with BI-2536 (an inhibitor of polo-like kinase 1), Fasudil suppressed KRAS-mutant lung cancer growth in a corresponding LSL-KRAS (G12D) mouse model and in a patient tumor explant mouse model of KRAS-mutant lung cancer [19].